Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells $68,350.15 in Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Greg Keenan sold 8,305 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the sale, the insider now owns 153,484 shares in the company, valued at approximately $1,263,173.32. The trade was a 5.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Greg Keenan also recently made the following trade(s):

• On Monday, March 3rd, Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total value of $97,912.00.

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock opened at $8.15 on Monday. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67. The business has a 50-day simple moving average of $8.08 and a 200 day simple moving average of $7.89. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -54.33 and a beta of 1.26.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AUPH. Invesco Ltd. boosted its holdings in shares of Aurinia Pharmaceuticals by 1.0% in the 4th quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company’s stock worth $1,294,000 after purchasing an additional 1,421 shares in the last quarter. Bridgefront Capital LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 12.9% in the 4th quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 1,891 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of Aurinia Pharmaceuticals by 3.2% in the 4th quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company’s stock worth $580,000 after purchasing an additional 2,000 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Aurinia Pharmaceuticals by 5.9% in the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 2,020 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares in the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.